Cantor says concerns over Amarin IP ‘making a mountain out of a molehill’

After speaking with the company and reviewing the public record of its patents and abbreviated new drug application-related matter, Cantor Fitzgerald analyst Louise Chen believes concerns over Amarin’s intellectual property are “making a mountain out of a molehill.” Vascepa’s intellectual property will keep out generics until August 2029, Chen tells investors in a research note. She sees peak sales potential of “billions of dollars” and reiterates an Overweight rating on Amarin with a $15 price target.

https://thefly.com/landingPageNews.php?id=2795643